Stay updated on Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedAdded a Blood Advances 2025 Dec 9 publication citation for Camidanlumab tesirine phase 2 study and removed the earlier Blood Advances online-ahead-of-print citation.SummaryDifference0.0%

- Check17 days agoChange DetectedLocations were expanded to include a comprehensive list of study sites (Arizona, California, Florida, Georgia, Illinois, Kentucky, Minnesota, Missouri, New Jersey, New York, Ohio, South Carolina, Texas, Virginia, Wisconsin, and British Columbia) and the study revision was updated from v3.3.2 to v3.3.3.SummaryDifference1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision: v3.3.2 replaces the previous v3.3.1 label on the page header/footer. This is a minor metadata update and does not affect the study details or navigation.SummaryDifference0.0%

- Check45 days agoChange DetectedPublications notes now clarify that the list is auto-populated from PubMed, and reflect Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedNotice regarding government funding status and NIH operation updates has been removed from the page. This change does not alter the study details, eligibility, outcomes, or how users interact with the page.SummaryDifference0.2%

- Check67 days agoChange DetectedNo significant changes detected; the page content, study details, eligibility criteria, and locations remain the same.SummaryDifference0.3%

Stay in the know with updates to Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page.